5:48 PM
 | 
Feb 08, 2010
 |  BC Extra  |  Top Story

Amgen presents denosumab data

Amgen Inc. (NASDAQ:AMGN) said denosumab met the primary endpoint of non-inferiority to Zometa zoledronic acid in time to the first on-study skeletal related event (SRE) in a Phase III trial to treat bone...

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >